Sign in
ACAD Stock Price, Chart, Stats & News
Acadia Pharmaceuticals Inc.
Save
Acadia Pharmaceuticals Inc. (ACAD) does not currently pay a dividend.
3.29B
Market cap
8.61x
Current P/E
25.19x
Forward P/E
ACAD chart
Fundamentals
Gross margin | 91.69% |
Operating margin | 9.78% |
Pretax margin | 12.96% |
Net margin | 36.49% |
Effective tax rate | -181.49% |
ROA | 25.00% |
ROE | 41.90% |
D/E | 0.04x |
Interest coverage ratio | – |
ACAD valuation
P/E | 8.61x |
P/S | 3.30x |
P/B | 2.86x |
P/CF | 31.99x |
P/FCF | 33.65x |
P/OCF | 31.99x |
PEG | 0.19x |
EV multiple | 27.88x |
About
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis.
Similar securities
Based on sector and market capitalization
Report issue